Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen NeuMoDx Human Adenovirus Assay Receives CE Mark

NEW YORK – Qiagen said on Thursday that its NeuMoDx HAdV Quant Assay for the identification and quantification of human adenovirus DNA has received CE-IVD certification.

Qiagen developed the assay in partnership with Sentinel Diagnostics, and the test adds to the current NeuMoDx transplant assay menu that already includes CE-marked tests for cytomegalovirus, Epstein-Barr virus, and BK virus viral load monitoring for the management of immunocompromised patients, such as those who have undergone organ transplantation.

All of these assays use Qiagen's automated, three-step NeuMoDx workflow that extracts DNA from blood or urine to isolate target nucleic acids followed by real-time PCR to target conserved sequences in the genomes of target viruses.

The new assay is also the 15th overall available on the NeuMoDx 96 and 288 Molecular Systems, which enables true random access of Qiagen-developed tests as well as laboratory-developed tests.

Qiagen acquired the remaining stake in NeuMoDx in September 2020 after having acquired a minority stake in the Ann Arbor, Michigan-based diagnostic developer in 2018 as part of a test menu development deal.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.